XML 60 R48.htm IDEA: XBRL DOCUMENT v3.25.2
Segment Reporting (Details)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
Jun. 30, 2024
USD ($)
Mar. 31, 2024
USD ($)
Jun. 30, 2025
USD ($)
numberOfSegments
Jun. 30, 2024
USD ($)
Segment Reporting [Abstract]            
Number of reportable segments | numberOfSegments         1  
Segment Reporting Information [Line Items]            
Revenues $ 10,739   $ 1,726   $ 12,503 $ 3,258
General and administrative 3,328   7,547   9,160 12,859
Restructuring costs 165 $ 12,400 0   12,538 0
Net Income (Loss) 2,523 $ (24,526) (19,796) $ (17,875) (22,003) (37,671)
Adjustments and reconciling items 0   0   0 0
Reportable Segment            
Segment Reporting Information [Line Items]            
Revenues 10,739   1,726   12,503 3,258
Research and development employee expense, lab supplies and overhead 2,297   6,908   6,733 14,008
Imdusiran IM-PROVE I, II & III clinical trials expense 1,405   4,010   3,789 9,399
AB-101-001 Phase 1a/1b clinical trial expense 1,738   3,186   3,637 5,996
Other early research and development programs expense 58   1,447   298 1,551
General and administrative 3,328   7,547   9,160 12,859
Restructuring costs 165   0   12,538 0
Other segment expense 267   253   590 490
Interest income 1,042   1,829   2,239 3,374
Net Income (Loss) $ 2,523   $ (19,796)   $ (22,003) $ (37,671)
Consolidated net loss 2,523   (19,796)   (22,003) (37,671)